A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms COSMIC-312
- Sponsors Exelixis
- 06 Dec 2018 New trial record
- 05 Dec 2018 According to an Ipsen media release, Ipsen will co-fund the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Genentech, is providing atezolizumab for use in this trial.
- 05 Dec 2018 Status changed from not yet recruiting to recruiting.